---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-027554"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-10-04T23:59:59+00:00"
generated_at: "2026-06-23T05:29:28.763633+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences CFO Thomas Freeburg resigns; continues as consultant and principal financial officer

## Summary
- CFO Thomas Freeburg resigned effective Sept 30, 2022; will serve as consultant and acting principal financial officer until new CFO hired.
- Severance of $127,500 (six months' base salary) payable over six months; equity awards scheduled to vest in 24 months fully accelerated.
- Consulting fee of $6,000/month for up to 20% time (~8 hrs/week); term from Sept 30, 2022 to Jan 30–Mar 30, 2023.
- Health and dental benefits continued for six months at Company expense; COBRA eligibility if elected.
- Company actively recruiting a replacement CFO.

## SEC filing metadata
- accession: 0001493152-22-027554
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-10-04T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/0001493152-22-027554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-027554
- JSON: https://secwatch.observer/filing/0001493152-22-027554.json
- Plain text: https://secwatch.observer/filing/0001493152-22-027554.txt

## Key facts
- Executive change
  Thomas Freeburg resigned as Chief Financial Officer at INTERPACE BIOSCIENCES, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On September 30, 2022 (the “Transition Date”), Thomas Freeburg, the Chief Financial Officer of Interpace Biosciences, Inc. ( the “Company”), resigned from his position as Chief Financial Officer and as an employee of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/0001493152-22-027554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.